Metabolic disease

Metabolic diseaseObesity has reached epidemic proportions and is associated with widespread health problems.

Chronic high-caloric intake and lack of exercise result in the storage of excess energy as lipid in body fat depots. The increases in body fat then trigger metabolic and inflammatory responses that lead to insulin resistance, type 2 diabetes, cardiovascular disease and increased risk of cancer.

Although changes in lifestyle are a first-line treatment option, most patients require additional therapeutic intervention.

DDB studies target G protein-coupled receptors as well as cytokine receptors, and focus on three main avenues for therapy of obesity and diabetes:

  • to modulate adipocyte metabolism
  • to activate glucose disposal in skeletal muscle
  • to enhance and preserve the release of insulin from pancreatic islets

.

Research laboratories

Analytical NeuropharmacologyCellular & Molecular Metabolism
 
Dr Celine Valant Prof Arthur Christopoulos   Prof Mark Febbraio
Endocrine & NeuropharmacologyMetabolic GPCR Biology
  
Dr Katie Leach Dr Karen Gregory  Prof Patrick Sexton A/Prof Denise Wootten
Molecular & Translational Drug DiscoveryReceptor Transducer Coupling
 
Dr Chris Langmead  Dr Sebastian Furness